Publicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (18)

2022

  1. Clinical Efficacy and Safety of Fanhdi®, a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study

    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, Vol. 28

  2. Current status of diagnosis and treatment of heparin-induced thrombocytopenia (HIT)

    Medicina Clinica, Vol. 158, Núm. 2, pp. 82-89

  3. Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH–SETH

    Clinical and Translational Oncology, Vol. 24, Núm. 5, pp. 770-783

2021

  1. A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients

    Blood Cells, Molecules, and Diseases, Vol. 86

  2. Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)

    Scientific Reports

2019

  1. Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations

    Revista Espanola de Cardiologia, Vol. 72, Núm. 9, pp. 749-759

  2. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia

    Scientific Reports, Vol. 9, Núm. 1

  3. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant

    Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 9, pp. 1825-1831

2017

  1. Clinical perspectives on the management of bleeding in patients on oral anticoagulants: The DECOVER Study (DElphi Consensus on oral COagulation and therapy action reVERsa

    Emergencias, Vol. 29, Núm. 1, pp. 18-26

2016

  1. Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines

    Annals of Hematology, Vol. 95, Núm. 7, pp. 1089-1098

2015

  1. Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score

    Leukemia Research, Vol. 39, Núm. 1, pp. 52-57

2014

  1. Venous leg ulcer in the context of chronic venous disease

    Phlebology, Vol. 29, Núm. 4, pp. 220-226

2013

  1. Negative impact of deep venous thrombosis on chronic venous disease

    Thrombosis Research, Vol. 131, Núm. 4

  2. Quality of life in patients with chronic venous disease: Influence of the socio-demographical and clinical factors

    International Angiology, Vol. 32, Núm. 4, pp. 433-441

2011

  1. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response

    Current Medical Research and Opinion, Vol. 27, Núm. 5, pp. 951-960

2009

  1. Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: A comparison of presenting clinical characteristics and response to treatment

    Annals of Hematology, Vol. 88, Núm. 10, pp. 973-978

2008

  1. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms

    Haematologica, Vol. 93, Núm. 5, pp. 729-734

2007

  1. Antithrombin Cambridge II (A384S): An underestimated genetic risk factor for venous thrombosis

    Blood, Vol. 109, Núm. 10, pp. 4258-4263